Abpro Holdings announced preclinical data for its HER2 x CD3 T-cell engager, ABP-102/CT-P72, will be presented at the American Association for Cancer Research Annual Meeting 2025. The presentation will focus on the drug’s selective targeting of HER2-overexpressing tumors while minimizing activity in normal tissues. Abpro is collaborating with Celltrion on the global development and commercialization of ABP-102/CT-P72.
This preclinical data presentation is an important step for Abpro. It offers an opportunity to validate their DiversImmune platform and showcase the potential of ABP-102/CT-P72 to a wider scientific and investment community. The data’s focus on selective targeting is crucial, addressing a key challenge in cancer therapy: minimizing harm to healthy tissues while effectively destroying cancer cells. Successful preclinical results could significantly increase investor interest and potentially pave the way for accelerated clinical development.
ABP-102/CT-P72 utilizes a tetravalent IgG1-[L]-scFv format, designed for optimized tumor selectivity and reduced cytokine-related toxicity. This bispecific antibody is being developed to treat various HER2-positive cancers, including breast, gastric, pancreatic, and colorectal cancers. The partnership with Celltrion provides Abpro with substantial resources and expertise in development and commercialization, particularly within the Asian market.
The upcoming presentation of preclinical data is a critical inflection point for ABP-102/CT-P72. Positive results could validate Abpro’s platform and significantly advance the drug’s development timeline. This could also attract further investment and partnerships, solidifying Abpro’s position in the competitive field of cancer immunotherapy. The specific data presented will be crucial in determining the next steps for ABP-102/CT-P72 and its potential impact on the treatment of HER2-positive cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
